Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
QbDVision provides a software platform designed to address digital transformation challenges in pharmaceutical and biotech manufacturing, helping companies manage compliance, quality, and process development.
2 investors
Qnity builds a quantum-electrochemical chip using nanogold-silicon electrodes and quantum sensing to perform ultra-sensitive, real-time molecular screening and binding affinity analysis across molecule sizes, from small organics to biologics. The platform targets pharmaceutical and drug discovery use cases, including therapeutic development, drug prediction validation, and precision diagnostics.
2 investors
Qoniq provides data analysis and knowledge synthesis tools for Medical and Scientific Affairs professionals, helping them work with complex scientific datasets while augmenting rather than replacing human expertise.
2 investors
Qu Biologics develops treatments aimed at cancer, chronic inflammatory diseases, and metabolic diseases by restoring normal immune function. It operates in the biotech and immunotherapy space.
2 investors
QualisureDx develops diagnostic tests using machine-learning and molecular analysis to identify unique cancer properties and guide personalized treatment decisions for oncologists. The company serves cancer care teams seeking to match patients with appropriate therapies that maximize efficacy while minimizing toxicity.
2 investors
QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates. The company operates in biotech, using computation to support drug discovery.
2 investors
QuberTech is a UK-based biotechnology company developing biotech tools to produce natural rubber from alternative crops grown in controlled environments, aiming to deliver traceable and sustainable materials. It targets the global natural rubber industry, addressing supply deficits, deforestation, and regulatory pressures such as the EU Deforestation Regulation.
2 investors
Qubit Pharmaceuticals develops novel drug candidates using quantum physics, AI, and computational chemistry through its ATLAS platform for high-precision molecular simulation, modeling, and molecule generation. Its pipeline focuses on oncology, inflammation, and antiviral/pandemic-response programs, with fully owned and partnered drug discovery projects.
2 investors
QUE Oncology develops Q-122, a non-hormonal therapeutic candidate in clinical development for treating vasomotor symptoms in postmenopausal women and cancer patients on hormone therapy. The company was formed as a joint venture between Emory University and University of Queensland's commercialization entity.
2 investors
2 investors
Qurcan develops veterinary pharmaceutical technology, with leadership holding advanced degrees in veterinary medicine, pharmaceutical sciences, and business development.
2 investors
QurieGen develops QuRIE-seq, a single-cell multi-omics platform that captures time-resolved single-cell data and trains lab-in-the-loop AI Virtual Cell models to predict cellular behavior and drug response. Spun out of the Huck Lab at Radboud University, the company serves pharmaceutical drug discovery and R&D.
2 investors
Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
2 investors
Radical Numerics develops AI models and architectures built for biology, including multimodal generative models trained on biological data to support genomic discovery and gene-editing. The company is behind the Evo and Evo 2 generative genomics models and aims to apply AI to biological research and biosecurity, including detection and response to biological threats.
2 investors
RadioNano Therapeutics develops boron neutron capture therapy (BNCT), an advanced radiotherapy targeting cancer cells. The company is commercializing RN-501, a nanoparticle-enhanced therapeutic drug aimed at improving treatment safety and efficacy for cancer patients.
2 investors
Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands. The company is headquartered in San Diego, California, and focuses on theranostic applications in oncology.
2 investors
2 investors
RapidPulse Medical is an investor relations page showcasing multiple healthcare-focused investment firms and incubators that back medical device and healthcare technology companies.
2 investors
Rapport is a biopharmaceutical company developing novel therapeutics. The company is led by a team with extensive experience in drug discovery, clinical development, and commercialization across neuroscience and rare disease indications.
2 investors
RareCan provides cancer treatment and clinical trial access tailored to individual patients, with a focus on improving outcomes for people diagnosed with rare cancers.
2 investors
Rarity Bioscience develops superRCA, a molecular detection technology that identifies DNA mutations with exceptional sensitivity for precision medicine applications. The company commercializes diagnostic assays and kits for clinical and research settings, with initial focus on leukemia and cancer detection.
2 investors
RayThera develops small molecule therapies targeting unmet needs in immunology. The company focuses on drug discovery in the biotechnology and immunology space.
2 investors
Re-Fresh Global pioneers textile waste recycling solutions using biotechnology to transform discarded textiles into new, sustainable resources. The company serves textile manufacturers and waste management operators in Europe and globally, addressing regulatory demand for circular textile economy solutions.
2 investors
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform. It serves researchers analyzing gene expression at subcellular resolution, including in FFPE and degraded samples.
2 investors